Vinorelbine Plus Cisplatin for Advanced Non-small-cell Lung Cancer

Mori Kiyoshi

doi:10.2482/haigan.43.872

This paper reviews the clinical outcomes presently achieved for the combination regimen of vinorel -bine (VNR) plus cisplatin (CDDP) in advanced non-small-cell lung cancer (NSCLC). The combination regimen (VC) was more effective than VNR alone, CDDP alone, or CDDP plus old drugs. The results were almost identical to those obtained for combination regimens of platinum plus other new drugs. The main adverse reactions were neutropenia and nausea/vomiting.<BR>Quality of life on VC was equivalent to that on platinum plus other new drugs. In terms of convenience, weekly VNR+CDDP (every 4 weeks) was inferior to paclitaxel+carboplatin (PCb) but appeared to be equivalent to VC every 3 weeks. The VC regimen is less expensive than PCb. There are problems with the dosing schedule of VNR in VC however, with VNR delivered on day 15 in less than 50% of patients receiving a regimen of VNR 25 mg/m²(weekly) and CDDP 80mg/m²(day 1) every 4 weeks. In contrast, analysis of data including that in our study revealed that the median delivered dose intensity was at least 90% for each course of CDDP and VNR (days 1 and 8) in a regimen of VNR 25mg/m²(days 1 and 8), CDDP 80 mg/m²(day 1) every 3 weeks, showing that VNR was administered almost in accordance with the schedule. The clinical outcome in a 3-weekly dosing schedule was a response rate of 29 to 57%, and mean survival was approximately 10 months. VC administered in a 3-weekly dosing schedule is therefore recommended.

Vinorelbine Plus Cisplatin for Advanced Non-small-cell Lung Cancer

Bibliographic Information

Search this article

Description

Journal

References(21)*help

Keywords

Details 詳細情報について

Export

Report a problem